Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia (Q33493174)

27 July 2017

1 reference

title

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia (English)

1 reference

27 July 2017

1 reference

James A McCubrey

6

0 references

Camilla Evangelisti

object named as

Camilla Evangelisti

2

0 references

author name string

Alberto M Martelli

1

1 reference

27 July 2017

Francesca Chiarini

3

1 reference

27 July 2017

Cecilia Grimaldi

4

1 reference

27 July 2017

Lucia Manzoli

5

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Investigational Drugs

27 July 2017

1 reference

27 July 2017

18

1 reference

27 July 2017

9

1 reference

27 July 2017

1333-1349

1 reference

Adult acute myeloid leukaemia.

27 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Progress in the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Differentiation therapy of acute myeloid leukemia: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

In vitro biology of human myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Deregulation of signaling pathways in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Activation of AKT kinases in cancer: implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Advances in protein kinase B signalling: AKTion on multiple fronts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PI3K/Akt: getting it right matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Should individual PI3 kinase isoforms be targeted in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Fine tuning the immune response with PI3K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Regulation of phosphoinositide 3-kinase expression in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The regulation and function of Class III PI3Ks: novel roles for Vps34.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Oncogenic signaling of class I PI3K isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PIKKing on PKB: regulation of PKB activity by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PI 3-kinase, Akt and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

mTOR, translation initiation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A complex interplay between Akt, TSC2 and the two mTOR complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The role of PTEN signaling perturbations in cancer and in targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The role of SHIP in cytokine-induced signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

SHIP is required for a functional hematopoietic stem cell niche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PHLiPPing the switch on Akt and protein kinase C signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Functional proteomic profiling of AML predicts response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Phosphorylation of the PTEN tail regulates protein stability and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A critical role for Lyn in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The phagocytes: neutrophils and monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

mTOR regulates cell survival after etoposide treatment in primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Synthesis and function of 3-phosphorylated inositol lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Small-molecule inhibitors of PDK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The FRB domain of mTOR: NMR solution structure and inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeting mTOR with rapamycin: one dose does not fit all

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeted drugs in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Is anticancer drug development heading in the right direction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Brain cancer stem cells display preferential sensitivity to Akt inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

The role of the PI3K-PKB signaling module in regulation of hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Imatinib resistance in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903136775

10.1517/14728220903136775

21 January 2018

Identifiers

DOI

1 reference

27 July 2017

1 reference